一小时后的负载葡萄糖与肥胖患者的多系统并发症有关
Ioanna Mixaki1, Michalis G Prokopakis2, Georgios Dimakopoulos3
1Medical School, Aristotle University, 54124 Thessaloniki, Greece.
Biomolecules
|February 27, 2026
概括
在口服葡萄糖耐受性测试期间血葡萄糖在1小时内升高与没有2型糖尿病的成年人中多种与肥胖有关的并发症有关. 这一发现强调了1小时葡萄糖作为代谢负担和肥胖风险分层的关键标志物.
科学领域:
- 代谢医学是一种代谢医学.
- 肥胖问题研究研究
- 心脏代谢健康状况
背景情况:
- 肥胖与许多健康并发症有关,这些并发症可能是2型糖尿病 (T2DM) 的前身.
- 早期识别代谢标记对于分层风险和指导肥胖相关并发症的治疗策略至关重要.
- 在口服葡萄糖耐受性测试 (OGTT) 中,负载后1小时的血葡萄糖是早期失糖症和心脏代谢风险的敏感指标.
研究的目的:
- 调查OGTT期间1小时后血葡萄糖水平与已确定的与肥胖有关的并发症之间的关联.
- 评估1小时葡萄糖作为肥胖但没有T2DM的成年人早期标志物的实用性.
主要方法:
- 一项观察性,横截面研究,涉及47名肥胖成人,没有T2DM.
- 标准75克OGTT与血葡萄糖和胰岛素测量在禁食时,1小时和2小时.
- 通过问卷,临床评估和医疗记录,回顾性收集有关肥胖相关并发症的数据.
主要成果:
- 负载后1小时较高的葡萄糖水平与动脉高血压,脂质失调,代谢功能障碍相关的脂肪性肝病,葡萄糖耐受性损失,肥胖低通风综合征,尿失禁和慢性病有显著联系.
- 与绝大多数并发症的禁食或2小时葡萄糖水平相比,1小时的葡萄糖显示出更高的辨别能力.
- 胰岛素水平表明普遍的胰岛素耐药性,但对区分并发症表型的能力有限.
结论:
- 在肥胖和没有T2DM的个体中,血葡萄糖在负载后1小时升高始终与多系统并发症有关.
- 1小时后负载葡萄糖作为临床相关的代谢和全身负担在肥胖症的综合标记.
- 研究结果支持使用1小时葡萄糖来对肥胖症的并发症驱动的风险分层,尽管由于研究设计,无法推断因果关系.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
2.5K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K
Insulin: Dosing Regimen and Adverse Effects
948
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
948
Hypoglycemia and Glucagon
1.1K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K
Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K
Carbohydrate Metabolism
14.6K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
14.6K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
324
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
324


